Copyright
©The Author(s) 2016.
World J Gastroenterol. Oct 28, 2016; 22(40): 8967-8977
Published online Oct 28, 2016. doi: 10.3748/wjg.v22.i40.8967
Published online Oct 28, 2016. doi: 10.3748/wjg.v22.i40.8967
Figure 7 Progress of hepatocellular carcinoma in one patient (case 3) who maintained stable disease for eight months.
The tumor size did not increase during the DFX administration period. A: Before deferasirox (DFX) administration; B: After one course of DFX therapy; C: After four courses of DFX therapy.
- Citation: Saeki I, Yamamoto N, Yamasaki T, Takami T, Maeda M, Fujisawa K, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Uchida K, Tani K, Sakaida I. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(40): 8967-8977
- URL: https://www.wjgnet.com/1007-9327/full/v22/i40/8967.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i40.8967